PL1989206T3 - Inhibitory enzymu aktywującego E1 - Google Patents

Inhibitory enzymu aktywującego E1

Info

Publication number
PL1989206T3
PL1989206T3 PL07763239T PL07763239T PL1989206T3 PL 1989206 T3 PL1989206 T3 PL 1989206T3 PL 07763239 T PL07763239 T PL 07763239T PL 07763239 T PL07763239 T PL 07763239T PL 1989206 T3 PL1989206 T3 PL 1989206T3
Authority
PL
Poland
Prior art keywords
inhibitors
activating enzyme
activating
enzyme
Prior art date
Application number
PL07763239T
Other languages
English (en)
Inventor
Steven P Langston
Edward J Olhava
Stepan Vyskocil
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38180115&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1989206(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of PL1989206T3 publication Critical patent/PL1989206T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL07763239T 2006-02-02 2007-01-31 Inhibitory enzymu aktywującego E1 PL1989206T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76448706P 2006-02-02 2006-02-02
EP07763239A EP1989206B1 (en) 2006-02-02 2007-01-31 Inhibitors of e1 activating enzyme
PCT/US2007/002560 WO2007092213A2 (en) 2006-02-02 2007-01-31 Inhibitors of e1 activating enzyme

Publications (1)

Publication Number Publication Date
PL1989206T3 true PL1989206T3 (pl) 2012-11-30

Family

ID=38180115

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07763239T PL1989206T3 (pl) 2006-02-02 2007-01-31 Inhibitory enzymu aktywującego E1

Country Status (28)

Country Link
US (6) US8207177B2 (pl)
EP (2) EP2402334B1 (pl)
JP (6) JP5231251B2 (pl)
KR (2) KR101450533B1 (pl)
CN (4) CN101379061B (pl)
AR (1) AR059308A1 (pl)
AU (1) AU2007212648C1 (pl)
BR (1) BRPI0707493B8 (pl)
CA (1) CA2639924C (pl)
CY (1) CY1113114T1 (pl)
DK (1) DK1989206T3 (pl)
EA (2) EA024006B1 (pl)
ES (2) ES2390921T3 (pl)
HK (2) HK1166308A1 (pl)
HR (1) HRP20120786T1 (pl)
IL (2) IL193141A (pl)
MY (2) MY171289A (pl)
NO (1) NO342745B1 (pl)
NZ (1) NZ570084A (pl)
PH (1) PH12013501772A1 (pl)
PL (1) PL1989206T3 (pl)
PT (1) PT1989206E (pl)
RS (1) RS52437B (pl)
SG (1) SG169369A1 (pl)
SI (1) SI1989206T1 (pl)
TW (2) TWI510486B (pl)
WO (1) WO2007092213A2 (pl)
ZA (1) ZA200806402B (pl)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
CA2639924C (en) * 2006-02-02 2017-01-10 Millennium Pharmaceuticals, Inc. Purinyl-and pyrrolo[2,3-d]pyrimidinyl cyclopentyl compounds and their use as inhibitors of e1 activating enzymes
GB0607948D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
PT2322525E (pt) * 2006-04-21 2013-12-26 Novartis Ag Derivados de purina para utilização como agonistas do recetor de adenosina a2a
GB0607953D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607944D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607945D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
EP1889846A1 (en) 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
WO2008019124A1 (en) * 2006-08-08 2008-02-14 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of e1 activating enzymes
EP1903044A1 (en) * 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
CA2669108A1 (en) * 2006-11-10 2008-05-15 Novartis Ag Cyclopentene diol monoacetate derivatives
AU2013204618B2 (en) * 2007-08-02 2015-11-05 Takeda Pharmaceutical Company Limited Process for the synthesis of E1 activating enzyme inhibitors
RU2553476C2 (ru) 2007-08-02 2015-06-20 Миллениум Фармасьютикалз, Инк. Способ синтеза ингибиторов е1-активирующего фермента
KR20100068286A (ko) * 2007-10-17 2010-06-22 노파르티스 아게 아데노신 ａ1 수용체 리간드로서의 퓨린 유도체
WO2010036213A1 (en) * 2008-09-26 2010-04-01 Agency For Science, Technology And Research 3-deazaneplanocin derivatives
UA104010C2 (en) * 2008-12-18 2013-12-25 Эли Лилли Энд Компани Purine compounds
RU2562245C2 (ru) * 2009-05-14 2015-09-10 Милленниум Фармасьютикалз, Инк. ГИДРОХЛОРИД (1S,2S,4R)-4-{ 4-[(1S)-2,3-ДИГИДРО-1Н-ИНДЕН-1-ИЛАМИНО]-7Н-ПИРРОЛО [2,3-d]ПИРИМИДИН-7-ИЛ} -2-ГИДРОКСИЦИКЛОПЕНТИЛ)МЕТИЛ СУЛЬФАМАТА
WO2012061551A1 (en) * 2010-11-05 2012-05-10 Millennium Pharmaceuticals, Inc. Administration of nedd8-activating enzyme inhibitor
CN103391939B (zh) 2010-12-03 2016-03-09 Epizyme股份有限公司 作为表观遗传酶调节剂的经取代的嘌呤和7-氮杂嘌呤化合物
US9394310B2 (en) 2010-12-03 2016-07-19 Epizyme, Inc. Carbocycle-substituted purine and 7-deazapurine compounds
EP2646454B1 (en) 2010-12-03 2015-07-08 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
EP2661436B1 (en) * 2011-01-07 2016-04-13 Leo Pharma A/S Novel sulfamide piperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof
WO2012158789A2 (en) 2011-05-17 2012-11-22 St. Jude Children's Research Hospital Methods and compositions for inhibiting neddylation of proteins
KR101230678B1 (ko) 2011-06-22 2013-02-07 이화여자대학교 산학협력단 Ｅ1 활성화 억제제인 ｍｌｎ4924의 제조방법
WO2013028832A2 (en) 2011-08-24 2013-02-28 Millennium Pharmaceuticals, Inc. Inhibitors of nedd8-activating enzyme
JP2015502137A (ja) * 2011-10-07 2015-01-22 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｅ１酵素変異体およびその用途
WO2013063496A1 (en) 2011-10-28 2013-05-02 Millennium Pharmaceuticals, Inc. Biomarkers of response to nae inhibitors
ES2668272T3 (es) 2011-11-03 2018-05-17 Millennium Pharmaceuticals, Inc. Administración de inhibidor de enzimas que activa NEDD8 y agente de hipometilación
MX352963B (es) 2012-02-17 2017-12-15 Millennium Pharm Inc Inhibidores de pirazolopirimidinilo en enzima activadora de ubiquitina.
JP2015524442A (ja) * 2012-08-03 2015-08-24 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｕｂａ６のインドール置換ピロロピリミジニル阻害剤
WO2014026198A1 (en) 2012-08-10 2014-02-13 Epizyme, Inc. Inhibitors of protein methyltransferase dot1l and methods of use thereof
US9597348B2 (en) 2012-09-06 2017-03-21 Epizyme, Inc. Method of treating leukemia
CN104822844B (zh) 2012-10-01 2019-05-07 米伦纽姆医药公司 预测对抑制剂的反应的生物标记物和方法以及其用途
CA2903303A1 (en) 2013-03-15 2014-09-25 Epizyme, Inc. Methods of synthesizing substituted purine compounds
EP2996773B1 (en) 2013-05-14 2020-09-16 Millennium Pharmaceuticals, Inc. Administration of nedd8-activating enzyme inhibitor and chemotherapeutic agents
CA2916468C (en) 2013-07-02 2019-07-23 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of sumo activating enzyme
WO2015013256A1 (en) * 2013-07-22 2015-01-29 Baylor College Of Medicine Non-ribose containing inhibitors of histone methyltransferase dot1l for cancer treatment
SG11201608441YA (en) 2014-06-24 2016-11-29 Taiho Pharmaceutical Co Ltd Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
BR112016030787B1 (pt) * 2014-07-01 2022-12-20 Takeda Pharmaceutical Company Limited Entidade química, composição farmacêutica e seu uso
EP3212650B1 (en) * 2014-10-29 2021-02-17 Millennium Pharmaceuticals, Inc. Administration of ubiquitin-activating enzyme inhibitor and chemotherapeutic agents
EP4115882A1 (en) 2015-01-16 2023-01-11 The General Hospital Corporation Compounds for improving mrna splicing
MX2017011778A (es) 2015-03-13 2017-12-04 Forma Therapeutics Inc Compuestos y composiciones de alfa-cinamida como inhibidores de histona desacetilasa 8 (hdac8).
CN105541810B (zh) * 2016-03-04 2019-05-17 南京工业大学 一种香豆素类nedd8激活酶抑制剂及其制备方法与应用
WO2017183927A1 (ko) * 2016-04-20 2017-10-26 한국화학연구원 신규한 헤테로고리 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
CN106008394B (zh) * 2016-05-23 2018-12-04 中国人民解放军第二军医大学 巯基苯并噻唑酰胺类化合物及其制备与作为药物的用途
CN106854208B (zh) * 2016-11-25 2019-04-09 成都柏睿泰生物科技有限公司 肿瘤抑制剂mln4924的合成方法
JP2020534331A (ja) * 2017-09-21 2020-11-26 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． （（１ｓ，２ｓ，４ｒ）−４−｛４−［（１ｓ）−２，３−ジヒドロ−１ｈ−インデン−１−イルアミノ］−７ｈ−ピロロ［２，３−ｄ］ピリミジン−７−イル｝−２−ヒドロキシシクロペンチル）メチルスルファメートの共結晶形態、その製剤及び使用
US20200377958A1 (en) 2017-12-01 2020-12-03 Millennium Pharmaceuticals, Inc. Biomarkers and methods for treatment with nae inhibitors
WO2019210392A1 (en) * 2018-05-03 2019-11-07 Her Majesty the Queen in the Right of Canada as represented by the Minister of Health Poxvirus host range protein k3 as a positive selection marker for generation of recombinant poxviruses, a therapeutic target for poxvirus infection and a therapeutic agent for pkr related diseases
EP3820475A4 (en) * 2018-07-09 2022-04-13 Takeda Pharmaceutical Company Limited ADMINISTRATION OF SUMO-ACTIVATING ENZYMIN HIBITOR AND ANTI-CD20 ANTIBODIES
CA3106520A1 (en) * 2018-07-13 2020-01-16 Il-2Rx, Inc. Compounds, compositions, methods, and uses for treating cancer and immunological disorders
CN110229067A (zh) * 2019-06-05 2019-09-13 南京焕然生物科技有限公司 一种2-氨基茚制备方法
CN112079836B (zh) * 2019-06-13 2022-12-13 中国科学院上海药物研究所 三唑并嘧啶类化合物及其盐、组合物和应用
KR20220158290A (ko) * 2020-02-21 2022-11-30 미토키닌, 인크. 신경퇴행성 및 미토콘드리아 질환의 치료를 위한 조성물 및 이를 사용하는 방법
KR20230096973A (ko) 2020-08-18 2023-06-30 인사이트 코포레이션 Jak 저해제를 제조하기 위한 방법 및 중간체
WO2022040172A1 (en) 2020-08-18 2022-02-24 Incyte Corporation Process and intermediates for preparing a jak1 inhibitor
WO2022112951A1 (en) 2020-11-25 2022-06-02 Takeda Pharmaceutical Company Limited Solid state forms of hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
CN112679505B (zh) * 2020-12-25 2022-04-22 杭州澳赛诺生物科技有限公司 一种4-甲基-7H-吡咯并[2,3-d]嘧啶的合成方法
CN112851671B (zh) * 2021-02-08 2022-03-29 南京思聚生物医药有限公司 一种4-取代的吡啶并[2,3-d]嘧啶-7-酮类化合物及其制备方法和应用
CN112939971B (zh) * 2021-02-08 2023-01-24 南京易腾药物研究院有限公司 一种香豆素类化合物及其制备方法和应用
WO2023023671A1 (en) * 2021-08-20 2023-02-23 Mitokinin, Inc. Compositions and methods for treatment of neurodegenerative and mitochondrial disease
WO2023025668A1 (en) 2021-08-25 2023-03-02 Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune Methods for the generation of stem cell memory t cells for adoptive t cell therapy
WO2024067676A1 (zh) * 2022-09-30 2024-04-04 微境生物医药科技(上海)有限公司 作为sumo活化酶抑制剂的化合物
WO2024099438A1 (zh) * 2022-11-11 2024-05-16 微境生物医药科技(上海)有限公司 作为sumo活化酶抑制剂的化合物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3622561A (en) 1969-08-18 1971-11-23 Univ Utah Nucleoside sugar esters of sulfamic acid and method for preparation of the same
JPS62108897A (ja) 1985-11-05 1987-05-20 Rikagaku Kenkyusho アスカマイシン誘導体及びその合成法並びに制癌剤
GB8813148D0 (en) 1988-06-03 1988-07-06 Glaxo Group Ltd Chemical compounds
GB8826205D0 (en) 1988-11-09 1988-12-14 Wellcome Found Heterocyclic compounds
US5674998A (en) 1989-09-15 1997-10-07 Gensia Inc. C-4' modified adenosine kinase inhibitors
US5726302A (en) 1989-09-15 1998-03-10 Gensia Inc. Water soluble adenosine kinase inhibitors
US5721356A (en) 1989-09-15 1998-02-24 Gensia, Inc. Orally active adenosine kinase inhibitors
US5763596A (en) 1989-09-15 1998-06-09 Metabasis Therapeutics, Inc. C-4' modified adenosine kinase inhibitors
US5864033A (en) 1989-09-15 1999-01-26 Metabasis Therapeutics, Inc. Adenosine kinase inhibitors
GB9325810D0 (en) 1993-12-17 1994-02-23 Zeneca Ltd Herbicidal composition
GB9325809D0 (en) 1993-12-17 1994-02-23 Zeneca Ltd Herbicidal composition
US6210917B1 (en) 1993-12-29 2001-04-03 The Regents Of The University Of California Method for suppressing multiple drug resistance in cancer cells
US5767097A (en) 1996-01-23 1998-06-16 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
US5973161A (en) 1996-03-18 1999-10-26 The University Of North Carolina At Chapel Hill Enantioselective synthesis of cyclopentenes
US5824657A (en) 1997-03-18 1998-10-20 Cubist Pharmaceuticals, Inc. Aminoacyl sulfamides for the treatment of hyperproliferative disorders
US6734283B1 (en) 1997-12-19 2004-05-11 Millennium Pharmaceuticals, Inc. Human proteins responsible for NEDD8 activation and conjugation
JPH11228446A (ja) 1998-02-16 1999-08-24 Mitsubishi Chemical Corp 抗マラリア剤
JPH11228422A (ja) 1998-02-16 1999-08-24 Mitsubishi Chemical Corp 抗マラリア剤
PT1411954E (pt) 2000-10-18 2011-03-16 Pharmasset Inc Nucleosídeos modificados para o tratamento de infecções virais e proliferação celular anormal
DE60236322D1 (de) 2001-12-07 2010-06-17 Vertex Pharma Verbindungen auf pyrimidin-basis als gsk-3-hemmer
AU2003248708A1 (en) 2002-06-17 2003-12-31 Isis Pharmaceuticals, Inc. Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation
WO2005007621A2 (en) * 2003-05-30 2005-01-27 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
EP1680431A1 (en) 2003-10-17 2006-07-19 Rigel Pharmaceuticals, Inc. Benzothiazole and thiazole'5,5-b!pyridine compositions and their use as ubiquitin ligase inhibitors
JP2008503591A (ja) * 2004-06-22 2008-02-07 ライジェル ファーマシューティカルズ， インコーポレイテッド ユビキチンリガーゼ阻害剤
RS52458B (en) 2005-02-04 2013-02-28 Millennium Pharmaceuticals Inc. E1 ENZYMING ENZYME INHIBITORS
CA2639924C (en) * 2006-02-02 2017-01-10 Millennium Pharmaceuticals, Inc. Purinyl-and pyrrolo[2,3-d]pyrimidinyl cyclopentyl compounds and their use as inhibitors of e1 activating enzymes

Also Published As

Publication number Publication date
SG169369A1 (en) 2011-03-30
AU2007212648A1 (en) 2007-08-16
KR20080091260A (ko) 2008-10-09
MY158106A (en) 2016-08-30
BRPI0707493A2 (pt) 2011-05-03
HK1124609A1 (en) 2009-07-17
MY171289A (en) 2019-10-07
IL193141A (en) 2017-10-31
TWI510486B (zh) 2015-12-01
EP2402334B1 (en) 2016-06-29
TW200800994A (en) 2008-01-01
BRPI0707493B1 (pt) 2021-01-05
PT1989206E (pt) 2012-10-15
AU2007212648B2 (en) 2013-04-04
US20130165457A9 (en) 2013-06-27
EA201500769A1 (ru) 2016-05-31
NZ570084A (en) 2011-07-29
EP2402334A1 (en) 2012-01-04
KR20140058655A (ko) 2014-05-14
CA2639924A1 (en) 2007-08-16
CN101379061B (zh) 2016-06-15
EA031335B1 (ru) 2018-12-28
KR101450533B1 (ko) 2014-10-16
US20190255052A1 (en) 2019-08-22
JP5231251B2 (ja) 2013-07-10
US20130289037A1 (en) 2013-10-31
DK1989206T3 (da) 2012-10-08
US20120258927A1 (en) 2012-10-11
EA024006B1 (ru) 2016-08-31
WO2007092213A2 (en) 2007-08-16
HK1166308A1 (zh) 2012-10-26
ZA200806402B (en) 2009-12-30
NO20083581L (no) 2008-08-19
JP2018027986A (ja) 2018-02-22
CN106008512B (zh) 2019-03-12
PH12013501772A1 (en) 2014-08-27
EP1989206A2 (en) 2008-11-12
JP2015083573A (ja) 2015-04-30
BRPI0707493B8 (pt) 2021-05-25
ES2390921T3 (es) 2012-11-19
WO2007092213A3 (en) 2007-10-11
JP2013103941A (ja) 2013-05-30
HRP20120786T1 (hr) 2012-11-30
IL232786A (en) 2017-10-31
EA200801784A1 (ru) 2009-04-28
JP2016147913A (ja) 2016-08-18
SI1989206T1 (sl) 2012-11-30
CN101379061A (zh) 2009-03-04
CY1113114T1 (el) 2016-04-13
CN103288835A (zh) 2013-09-11
US20170136024A1 (en) 2017-05-18
CN106008512A (zh) 2016-10-12
NO342745B1 (no) 2018-08-06
IL232786A0 (en) 2014-07-31
US20120258977A1 (en) 2012-10-11
KR101450535B1 (ko) 2014-10-14
US8207177B2 (en) 2012-06-26
IL193141A0 (en) 2009-02-11
CA2639924C (en) 2017-01-10
US20070191293A1 (en) 2007-08-16
AR059308A1 (es) 2008-03-26
JP2009528986A (ja) 2009-08-13
JP6199851B2 (ja) 2017-09-20
JP2020055841A (ja) 2020-04-09
AU2007212648C1 (en) 2017-02-23
RS52437B (en) 2013-02-28
ES2593433T3 (es) 2016-12-09
TW201509938A (zh) 2015-03-16
CN110003216A (zh) 2019-07-12
EP1989206B1 (en) 2012-07-04

Similar Documents

Publication Publication Date Title
IL232786A0 (en) Inhibitors of e1 enzyme activators
ME02012B (me) INHIBITORI El AKTIVIRAJUĆIH ENZIMA
IL254784A0 (en) Heteroaryl compounds for use as inhibitors of e1-activating enzymes
GB0619753D0 (en) Enzyme inhibitors
ZA200807135B (en) Azolopyridin-3-one derivatives as inhibitors of endothelial lipase
HK1129298A1 (en) Dihydrodiazepines useful as inhibitors of protein kinases
IL194339A0 (en) Enzyme inhibitors
EP2026843A4 (en) THERAPEUTIC USES OF RTP801L INHIBITORS
ZA200808282B (en) Uses of DPP-IV inhibitors
IL194699A0 (en) Tetrahydropteridines useful as inhibitors of protein kinases
EP2047864A4 (en) USE OF INHIBITOR OF RPN2 GENE EXPRESSION
EP2007383A4 (en) INHIBITORS OF PROTEIN PRENYLTRANSFERASES
ZA201000482B (en) Process for the synthesis of e1 activating enzyme inhibitors
ZA200806871B (en) Dihydrodiazepines useful as inhibitors of protein kinases
GB0608821D0 (en) DHFR enzyme inhibitors
GB0608844D0 (en) Enzyme inhibitors
GB0617161D0 (en) Enzyme inhibitors
EP2067859A4 (en) USE OF AN ACTIVATED CYTOKININ BIOSYNTHETIZING ENZYME
IL198803A0 (en) Selective inhibitors of neurotensin degrading enzymes
GB0608855D0 (en) Inhibitors of MAP kinase enzymes
GB0621283D0 (en) Inhibitors of PLK Enzymes
ZA200808237B (en) Enzyme inhibitors
GB0624958D0 (en) Enzyme inhibitors
GB0620884D0 (en) Enzyme inhibitors
GB0612544D0 (en) Enzyme inhibitors